GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Capex-to-Operating-Cash-Flow

Biolife Sciences (Biolife Sciences) Capex-to-Operating-Cash-Flow : 0.00 (As of May. 2008)


View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Biolife Sciences's Capital Expenditure for the three months ended in May. 2008 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in May. 2008 was $-0.11 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Biolife Sciences Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Biolife Sciences's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Capex-to-Operating-Cash-Flow Chart

Biolife Sciences Annual Data
Trend Nov04 Nov05 Nov06 Nov07
Capex-to-Operating-Cash-Flow
- - - -

Biolife Sciences Quarterly Data
Feb05 May05 Aug05 Nov05 Feb06 May06 Aug06 Nov06 Feb07 May07 Aug07 Nov07 Feb08 May08
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biolife Sciences's Capex-to-Operating-Cash-Flow

For the Medical Instruments & Supplies subindustry, Biolife Sciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolife Sciences's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's Capex-to-Operating-Cash-Flow falls into.



Biolife Sciences Capex-to-Operating-Cash-Flow Calculation

Biolife Sciences's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Nov. 2007 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.285
=N/A

Biolife Sciences's Capex-to-Operating-Cash-Flow for the quarter that ended in May. 2008 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.108
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolife Sciences  (OTCPK:BLFE) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Biolife Sciences Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolife Sciences (Biolife Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052
Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.
Executives
Arthur Viola director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired 09-15-2020